These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12585946)

  • 21. [Angiotensin 1-antagonists: primary therapeutic option in arterial hypertension, too].
    Traut
    Dtsch Med Wochenschr; 2003 Jan; 128(4):161; discussion 161-2. PubMed ID: 12589590
    [No Abstract]   [Full Text] [Related]  

  • 22. [To protect the hypertensive patient from complications. Blood pressure lowering is not equal to blood pressure lowering].
    MMW Fortschr Med; 2003 Nov; 145(45):51. PubMed ID: 14712789
    [No Abstract]   [Full Text] [Related]  

  • 23. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.
    Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ
    Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Losartan for cardiovascular disease in patient's with and without diabetes in the LIFE study.
    Cruickshank JM
    Lancet; 2002 Jun; 359(9324):2200-1; author reply 2203-4. PubMed ID: 12091004
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy of hypertension in patients with atrial fibrillation. Sartan is superior to beta-blocker].
    MMW Fortschr Med; 2003 May; 145(19):53. PubMed ID: 12813983
    [No Abstract]   [Full Text] [Related]  

  • 26. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
    Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
    J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Isolated systolic hypertension. "AT1 blocker preferred over beta-blocker"].
    MMW Fortschr Med; 2002 Sep; 144(38):14. PubMed ID: 12395694
    [No Abstract]   [Full Text] [Related]  

  • 29. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
    Devereux RB; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results from the LIFE study: promising effects of new hypertensive agents].
    Nilsson P; Kahan T
    Lakartidningen; 2002 Apr; 99(16):1792-4. PubMed ID: 12043477
    [No Abstract]   [Full Text] [Related]  

  • 31. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
    Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
    Dahlöf B; Devereux RB; Kjeldsen SE; Julius S; Beevers G; de Faire U; Fyhrquist F; Ibsen H; Kristiansson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H;
    Lancet; 2002 Mar; 359(9311):995-1003. PubMed ID: 11937178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for antihypertensive treatment in patients with obstructive sleep apnea.
    Kraiczi H; Hedner J; Peker Y; Grote L
    Am J Respir Crit Care Med; 2000 May; 161(5):1423-8. PubMed ID: 10806134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of hypertensive patients with cardiovascular damage].
    Tomiyama H; Takata Y; Yamashina A
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():612-6. PubMed ID: 15171444
    [No Abstract]   [Full Text] [Related]  

  • 35. [German Hypertension League on the LIFE Study. New evaluation of AT1 receptor antagonists].
    Dominiak P; Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):47. PubMed ID: 12395703
    [No Abstract]   [Full Text] [Related]  

  • 36. Angiotensin II inhibition and prevention of atrial fibrillation and stroke.
    Bourassa MG
    J Am Coll Cardiol; 2005 Mar; 45(5):720-1. PubMed ID: 15734616
    [No Abstract]   [Full Text] [Related]  

  • 37. [What are the consequences of the LIFE Study for general practice].
    Zidek W
    MMW Fortschr Med; 2002 Sep; 144(38):48. PubMed ID: 12395704
    [No Abstract]   [Full Text] [Related]  

  • 38. [Young patient with mild hypertension: angiotensin inhibitor or beta blocker?].
    Girndt M
    MMW Fortschr Med; 2011 Sep; 153(38):17. PubMed ID: 21977791
    [No Abstract]   [Full Text] [Related]  

  • 39. [Kidney protection leads to heart protection, too].
    MMW Fortschr Med; 2006 Aug; 148(33-34):57. PubMed ID: 16981393
    [No Abstract]   [Full Text] [Related]  

  • 40. Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers.
    Schiffrin EL
    Can J Cardiol; 2002 May; 18 Suppl A():15A-18A. PubMed ID: 12045789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.